• In August 2026, Cybin Inc. reported a first-quarter net loss of US$47.82 million, with basic and diluted loss per share from continuing operations of US$0.91, while Helus Pharma appointed experienced HR leader Regina Donohue as Chief People Officer and CNS drug-development expert Suresh Durgam, M.D., to its Scientific Advisory Board.
• Investor interest in Cybin has been influenced by its psychedelic medicine pipeline progress, including HLP003 entering a Phase 3 trial for major depressive disorder, and by confidence in refreshed leadership as the broader field of psychedelic-based mental health therapies gains momentum.
• We will now examine how Cybin’s wider clinical progress and leadership reshaping could influence its existing investment narrative and risk profile.

Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 30 best rare earth metal stocks of the very few that mine this essential strategic resource.

Cybin Investment Narrative Recap

To own Cybin, you need to believe that its psychedelic-based treatments can translate advancing trials into an approved therapy and, eventually, a viable business model despite ongoing losses. The key short term catalyst remains clinical progress in its lead programs, while the biggest risk is continued heavy cash burn without offsetting revenue. The latest quarterly loss and Helus leadership hires around HLP003 do not materially change that balance yet, but they sharpen the focus on execution.

The most relevant recent announcement is Cybin’s first quarter 2026 result, showing a net loss of US$47.82 million and no revenue. Against a backdrop of HLP003 moving through Phase 3, this underscores how dependent the story still is on future clinical and regulatory outcomes. Until there is clearer visibility on approvals or partnerships, ongoing operating losses remain central to Cybin’s risk profile and to how investors weigh the upside of its pipeline.

Yet beneath the enthusiasm for psychedelic therapies, investors should be aware that persistent losses and funding needs could...

Cybin's narrative projects $275.1 million revenue and $60.3 million earnings by 2029. This implies an earnings increase of about $231.5 million from -$171.2 million today.

Uncover how Cybin's forecasts yield a $41.62 fair value, a 198% upside to its current price.

Exploring Other Perspectives

Before this news, the most optimistic analysts were assuming revenue could reach about US$565.4 million by 2029, which is far bolder than consensus and rests heavily on CYB003 and CYB004 clearing clinical, regulatory and adoption hurdles that now look more finely balanced in light of rising quarterly losses and evolving leadership at Helus.

Explore 7 other fair value estimates on Cybin - why the stock might be worth 44% less than the current price!

Form Your Own Verdict

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Cybin research is our analysis highlighting 2 key rewards and 6 important warning signs that could impact your investment decision.
• Our free Cybin research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Cybin's overall financial health at a glance.

Want Some Alternatives?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• Capitalize on the AI infrastructure supercycle with our selection of the 55 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• Outshine the giants: these 18 early-stage AI stocks could fund your retirement.
• AI is about to change healthcare. These 42 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.